- Home
- GLAD vs MLTX Comparison
GLAD vs MLTX Comparison
Compare GLAD & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- MLTX
- Stock Information
- Founded
- GLAD 2001
- MLTX 2021
- Country
- GLAD United States
- MLTX Switzerland
- Employees
- GLAD N/A
- MLTX 100
- Industry
- GLAD Finance/Investors Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- MLTX Health Care
- Exchange
- GLAD Nasdaq
- MLTX Nasdaq
- Market Cap
- GLAD 482.1M
- MLTX 595.6M
- IPO Year
- GLAD N/A
- MLTX N/A
- Fundamental
- Price
- GLAD $19.59
- MLTX $10.46
- Analyst Decision
- GLAD Hold
- MLTX Buy
- Analyst Count
- GLAD 3
- MLTX 9
- Target Price
- GLAD $24.83
- MLTX $37.63
- AVG Volume (30 Days)
- GLAD 248.4K
- MLTX 10.3M
- Earning Date
- GLAD 11-12-2025
- MLTX 11-06-2025
- Dividend Yield
- GLAD 10.04%
- MLTX N/A
- EPS Growth
- GLAD N/A
- MLTX N/A
- EPS
- GLAD 3.38
- MLTX N/A
- Revenue
- GLAD $88,900,000.00
- MLTX N/A
- Revenue This Year
- GLAD N/A
- MLTX N/A
- Revenue Next Year
- GLAD $17.16
- MLTX N/A
- P/E Ratio
- GLAD $5.84
- MLTX N/A
- Revenue Growth
- GLAD N/A
- MLTX N/A
- 52 Week Low
- GLAD $19.59
- MLTX $5.95
- 52 Week High
- GLAD $30.43
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- GLAD 14.24
- MLTX 24.88
- Support Level
- GLAD $20.41
- MLTX $8.18
- Resistance Level
- GLAD $21.89
- MLTX $7.48
- Average True Range (ATR)
- GLAD 0.48
- MLTX 1.77
- MACD
- GLAD -0.14
- MLTX -2.13
- Stochastic Oscillator
- GLAD 0.00
- MLTX 7.32
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.